Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Autoimmune Disorders

  Free Subscription


Articles published in J Neurol

Retrieve available abstracts of 226 articles:
HTML format



Single Articles


    December 2022
  1. MOCCIA M, Affinito G, Berera G, Marrazzo G, et al
    Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.
    J Neurol. 2022;269:6504-6511.
    PubMed     Abstract available


  2. PAKEERATHAN T, Havla J, Schwake C, Salmen A, et al
    Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode.
    J Neurol. 2022;269:6366-6376.
    PubMed     Abstract available


    November 2022
  3. FILIPPI M, Preziosa P, Arnold DL, Barkhof F, et al
    Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective.
    J Neurol. 2022 Nov 24. doi: 10.1007/s00415-022-11488.
    PubMed     Abstract available


  4. MIRMOSAYYEB O, Zivadinov R, Weinstock-Guttman B, Benedict RHB, et al
    Optical coherence tomography (OCT) measurements and cognitive performance in multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2022 Nov 17. pii: 10.1007/s00415-022-11449.
    PubMed     Abstract available


  5. KWON YN, Woodhall M, Sung JJ, Kim KK, et al
    Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis.
    J Neurol. 2022 Nov 17. pii: 10.1007/s00415-022-11458.
    PubMed     Abstract available


  6. KIM S, Kim KH, Chung HY, Park HJ, et al
    Anti-titin antibodies are associated with myocarditis in patients with myasthenia gravis.
    J Neurol. 2022 Nov 16. pii: 10.1007/s00415-022-11485.
    PubMed     Abstract available


  7. PENNINGTON P, Weinstock-Guttman B, Kolb C, Jakimovski D, et al
    Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
    J Neurol. 2022 Nov 14. pii: 10.1007/s00415-022-11405.
    PubMed     Abstract available


  8. GALPERIN I, Mirelman A, Schmitz-Hubsch T, Hsieh KL, et al
    Treadmill training with virtual reality to enhance gait and cognitive function among people with multiple sclerosis: a randomized controlled trial.
    J Neurol. 2022 Nov 11. pii: 10.1007/s00415-022-11469.
    PubMed     Abstract available


  9. DE ROSA AP, Esposito F, Valsasina P, d'Ambrosio A, et al
    Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative.
    J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11479.
    PubMed     Abstract available


  10. SIMPSON R, Posa S, Langer L, Bruno T, et al
    A systematic review and meta-analysis exploring the efficacy of mindfulness-based interventions on quality of life in people with multiple sclerosis.
    J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11451.
    PubMed     Abstract available


  11. TERESHKO Y, Gigli GL, Pez S, De Pellegrin A, et al
    New-onset Myasthenia Gravis after SARS-CoV-2 infection: case report and literature review.
    J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11472.
    PubMed     Abstract available


  12. NIINO M, Fukumoto S, Okuno T, Sanjo N, et al
    Health-related quality of life in Japanese patients with multiple sclerosis.
    J Neurol. 2022 Nov 5. pii: 10.1007/s00415-022-11453.
    PubMed     Abstract available


  13. KURI A, Vickaryous N, Awad A, Jacobs BM, et al
    Vitamin D genetic risk scores in multiple sclerosis.
    J Neurol. 2022 Nov 5. pii: 10.1007/s00415-022-11466.
    PubMed     Abstract available


  14. JARIUS S, Haas J, Wildemann B
    Rho GTPase-activating protein 17 (ARHGAP17) as additional autoimmune target in ARHGAP26-IgG/anti-Ca autoantibody-associated autoimmune encephalitis.
    J Neurol. 2022 Nov 4. pii: 10.1007/s00415-022-11417.
    PubMed    


  15. STRANO CMM, Sorrenti B, Bosco L, Falzone YM, et al
    Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report.
    J Neurol. 2022;269:6152-6154.
    PubMed    


    October 2022
  16. OMARY R, Bockisch CJ, De Vere-Tyndall A, Pazahr S, et al
    Lesion follows function: video-oculography compared with MRI to diagnose internuclear ophthalmoplegia in patients with multiple sclerosis.
    J Neurol. 2022 Oct 31. pii: 10.1007/s00415-022-11428.
    PubMed     Abstract available


  17. WUSCHEK A, Bussas M, El Husseini M, Harabacz L, et al
    Somatosensory evoked potentials and magnetic resonance imaging of the central nervous system in early multiple sclerosis.
    J Neurol. 2022 Oct 7. pii: 10.1007/s00415-022-11407.
    PubMed     Abstract available


  18. PREZIOSA P, Pagani E, Meani A, Marchesi O, et al
    NODDI, diffusion tensor microstructural abnormalities and atrophy of brain white matter and gray matter contribute to cognitive impairment in multiple sclerosis.
    J Neurol. 2022 Oct 6. pii: 10.1007/s00415-022-11415.
    PubMed     Abstract available


  19. COSTELLO F, Burton JM
    Contemporary management challenges in seropositive NMOSD.
    J Neurol. 2022;269:5674-5681.
    PubMed     Abstract available


  20. KANG L, Wan C
    Paraneoplastic syndrome in neuroophthalmology.
    J Neurol. 2022;269:5272-5282.
    PubMed     Abstract available


  21. LEVI-STRAUSS J, Provost C, Wane N, Jacquemont T, et al
    NMOSD typical brain lesions after COVID-19 mRNA vaccination.
    J Neurol. 2022;269:5213-5215.
    PubMed    


  22. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset.
    J Neurol. 2022;269:5319-5327.
    PubMed     Abstract available


    September 2022
  23. ZHANG S, Yang S, Lu J, Liu S, et al
    CIDP-like autoimmune nodopathy complicated with focal segmental glomerulosclerosis: a case study and literature review.
    J Neurol. 2022 Sep 30. pii: 10.1007/s00415-022-11369.
    PubMed     Abstract available


  24. STASCHEIT F, Grittner U, Hoffmann S, Mergenthaler P, et al
    Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis.
    J Neurol. 2022 Sep 27. pii: 10.1007/s00415-022-11389.
    PubMed     Abstract available


  25. MARGONI M, Pagani E, Preziosa P, Palombo M, et al
    In vivo quantification of brain soma and neurite density abnormalities in multiple sclerosis.
    J Neurol. 2022 Sep 24. pii: 10.1007/s00415-022-11386.
    PubMed     Abstract available


  26. PAGANI E, Storelli L, Pantano P, Petsas N, et al
    Multicenter data harmonization for regional brain atrophy and application in multiple sclerosis.
    J Neurol. 2022 Sep 24. pii: 10.1007/s00415-022-11387.
    PubMed     Abstract available


  27. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
    Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
    J Neurol. 2022 Sep 22. pii: 10.1007/s00415-022-11385.
    PubMed    


  28. FILSER M, Buchner A, Fink GR, Gold SM, et al
    The manifestation of affective symptoms in multiple sclerosis and discussion of the currently available diagnostic assessment tools.
    J Neurol. 2022 Sep 21. pii: 10.1007/s00415-022-11359.
    PubMed     Abstract available


  29. CHAPPUIS M, Rousseau C, Bajeux E, Wiertlewski S, et al
    Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis.
    J Neurol. 2022 Sep 16. pii: 10.1007/s00415-022-11341.
    PubMed     Abstract available


  30. REYES-VEGA MF, Soto-Cabezas MG, Soriano-Moreno AN, Valle-Campos A, et al
    Clinical features of Guillain-Barre syndrome and factors associated with mortality during the 2019 outbreak in Peru.
    J Neurol. 2022 Sep 13. pii: 10.1007/s00415-022-11331.
    PubMed     Abstract available


  31. NICOLAS P, Marion-Moffet H, Gossez M, Vukusic S, et al
    Anti-SARS-CoV-2 humoral and cellular responses in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies.
    J Neurol. 2022 Sep 12. pii: 10.1007/s00415-022-11353.
    PubMed    


  32. MAIER A, Kapfenberger R, Katona I, Weis J, et al
    Nonregional small fibre neuropathy in cases of autoimmune autonomic neuropathy.
    J Neurol. 2022 Sep 9. pii: 10.1007/s00415-022-11340.
    PubMed     Abstract available


  33. CAPASSO N, Palladino R, Cerbone V, Spiezia AL, et al
    Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study.
    J Neurol. 2022 Sep 1. pii: 10.1007/s00415-022-11350.
    PubMed     Abstract available


    August 2022
  34. WOELFLE T, Pless S, Reyes O, Wiencierz A, et al
    Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study.
    J Neurol. 2022 Aug 30. pii: 10.1007/s00415-022-11306.
    PubMed     Abstract available


  35. GUEGUEN A, Hijazi B, Zuber K, Deschamps R, et al
    Generalization of ocular myasthenia gravis 10 years after onset.
    J Neurol. 2022 Aug 24. pii: 10.1007/s00415-022-11316.
    PubMed     Abstract available


  36. BARNAY M, Duval F, Sole G, Carla L, et al
    Usefulness of subcutaneous immunoglobulin therapy in the management of myasthenia gravis: a retrospective cohort study.
    J Neurol. 2022 Aug 22. pii: 10.1007/s00415-022-11345.
    PubMed     Abstract available


  37. LEHNERER S, Jacobi J, Schilling R, Grittner U, et al
    Correction to: Burden of disease in myasthenia gravis: taking the patient's perspective.
    J Neurol. 2022 Aug 12. pii: 10.1007/s00415-022-11290.
    PubMed    


  38. JAFARPOUR S, Banerjee A, Boyd NK, Vogel BN, et al
    Association of rare variants in genes of immune regulation with pediatric autoimmune CNS diseases.
    J Neurol. 2022 Aug 12. pii: 10.1007/s00415-022-11325.
    PubMed     Abstract available


  39. FEINSTEIN A, Amato MP, Brichetto G, Chataway J, et al
    The late onset of emotional distress in people with progressive multiple sclerosis during the Covid-19 pandemic: longitudinal findings from the CogEx study.
    J Neurol. 2022 Aug 8. pii: 10.1007/s00415-022-11295.
    PubMed     Abstract available


  40. KREFT KL, Robertson NP
    Innovative biomarkers to predict unfavourable outcomes after initiating multiple sclerosis treatment.
    J Neurol. 2022 Aug 1. pii: 10.1007/s00415-022-11300.
    PubMed    


    July 2022
  41. DORON A, Piura Y, Vigiser I, Kolb H, et al
    BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves.
    J Neurol. 2022 Jul 30. pii: 10.1007/s00415-022-11303.
    PubMed     Abstract available


  42. CAPUANO R, Altieri M, Conte M, Bisecco A, et al
    Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod.
    J Neurol. 2022 Jul 26. pii: 10.1007/s00415-022-11296.
    PubMed     Abstract available


  43. BLACKMAN G, Lim MF, Pollak T, Al-Diwani A, et al
    The clinical relevance of serum versus CSF NMDAR autoantibodies associated exclusively with psychiatric features: a systematic review and meta-analysis of individual patient data.
    J Neurol. 2022 Jul 5. pii: 10.1007/s00415-022-11224.
    PubMed     Abstract available


  44. MUNOZ-JURADO A, Escribano BM, Aguera E, Caballero-Villarraso J, et al
    SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.
    J Neurol. 2022 Jul 5. pii: 10.1007/s00415-022-11237.
    PubMed     Abstract available


  45. TAN X, Liu Y, Wu X, Guo Y, et al
    Guillain-Barre-like syndrome: an uncommon feature of CASPR2 and LGI1 autoimmunity.
    J Neurol. 2022 Jul 3. pii: 10.1007/s00415-022-11248.
    PubMed     Abstract available


  46. EID K, Torkildsen O, Aarseth J, Celius EG, et al
    Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy.
    J Neurol. 2022 Jul 3. pii: 10.1007/s00415-022-11249.
    PubMed     Abstract available


  47. MERGENTHALER P, Stetefeld HR, Dohmen C, Kohler S, et al
    Seronegative myasthenic crisis: a multicenter analysis.
    J Neurol. 2022;269:3904-3911.
    PubMed     Abstract available


  48. ALCALA C, Cubas L, Carratala S, Gascon F, et al
    NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.
    J Neurol. 2022;269:3495-3500.
    PubMed     Abstract available


    June 2022
  49. CANNIZZARO M, Ferre L, Clarelli F, Giordano A, et al
    Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients.
    J Neurol. 2022 Jun 27. pii: 10.1007/s00415-022-11227.
    PubMed     Abstract available


  50. SOROSINA M, Barizzone N, Clarelli F, Anand S, et al
    Correction to: A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
    J Neurol. 2022 Jun 25. pii: 10.1007/s00415-022-11216.
    PubMed    


  51. LEGUY S, Lefort M, Lescot L, Michaud A, et al
    COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients.
    J Neurol. 2022 Jun 23. pii: 10.1007/s00415-022-11215.
    PubMed     Abstract available


  52. SANDROFF BM, Motl RW, Roman CAF, Wylie GR, et al
    Thalamic atrophy moderates associations among aerobic fitness, cognitive processing speed, and walking endurance in persons with multiple sclerosis.
    J Neurol. 2022 Jun 19. pii: 10.1007/s00415-022-11205.
    PubMed     Abstract available


  53. DORCET G, Migne H, Biotti D, Bost C, et al
    Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression.
    J Neurol. 2022 Jun 2. pii: 10.1007/s00415-022-11197.
    PubMed     Abstract available


  54. ARINO H, Heartshorne R, Michael BD, Nicholson TR, et al
    Neuroimmune disorders in COVID-19.
    J Neurol. 2022;269:2827-2839.
    PubMed     Abstract available


  55. YOGANATHAN K, Stevenson A, Tahir A, Sadler R, et al
    Bedside and laboratory diagnostic testing in myasthenia.
    J Neurol. 2022;269:3372-3384.
    PubMed     Abstract available


  56. LAMBERT N, Lutteri L, Tshibanda L, Bianchi E, et al
    Anti-SOX1 antibody-associated acute hemorrhagic leukoencephalitis.
    J Neurol. 2022;269:3359-3362.
    PubMed    


  57. JENTZER A, Carra-Dalliere C, Lozano C, Riviere S, et al
    Neuromyelitis optica spectrum disorder following COVID-19 infection with increase in pre-existing anti-aquaporin-4 antibodies.
    J Neurol. 2022;269:2850-2853.
    PubMed    


  58. AYVACIOGLU CAGAN C, Temucin CM, Arslan D, Gocmen R, et al
    Isolated spinal cord granulomatous angiitis: a case report and review of the literature.
    J Neurol. 2022;269:3175-3179.
    PubMed     Abstract available


  59. VAN ROSMALEN MHJ, Froeling M, Mandija S, Hendrikse J, et al
    MRI of the intraspinal nerve roots in patients with chronic inflammatory neuropathies: abnormalities correlate with clinical phenotypes.
    J Neurol. 2022;269:3159-3166.
    PubMed     Abstract available


  60. ZIEMSSEN T, Lang M, Schmidt S, Albrecht H, et al
    Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
    J Neurol. 2022;269:3276-3285.
    PubMed     Abstract available


  61. AKAISHI T, Misu T, Fujihara K, Takahashi T, et al
    Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
    J Neurol. 2022;269:3136-3146.
    PubMed     Abstract available


  62. DI SABATINO E, Gaetani L, Sperandei S, Fiacca A, et al
    The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI.
    J Neurol. 2022;269:3129-3135.
    PubMed     Abstract available


  63. MISCIOSCIA A, Puthenparampil M, Miante S, Pengo M, et al
    Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis.
    J Neurol. 2022 Jun 1. pii: 10.1007/s00415-022-11183.
    PubMed     Abstract available


    May 2022
  64. HRASTELJ J, Robertson NP
    A role for the Epstein-Barr virus in multiple sclerosis aetiology?
    J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11177.
    PubMed    


  65. GOLD R, Piani-Meier D, Kappos L, Bar-Or A, et al
    Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
    J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11166.
    PubMed     Abstract available


  66. JARIUS S, Komorowski L, Regula JU, Haas J, et al
    Rho GTPase-activating protein 10 (ARHGAP10/GRAF2) is a novel autoantibody target in patients with autoimmune encephalitis.
    J Neurol. 2022 May 27. pii: 10.1007/s00415-022-11178.
    PubMed     Abstract available


  67. WILLISON AG, Ruck T, Lenz G, Hartung HP, et al
    Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
    J Neurol. 2022 May 24. pii: 10.1007/s00415-022-11158.
    PubMed    


  68. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
    Early use of high-efficacy diseasemodifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
    J Neurol. 2022 May 24. pii: 10.1007/s00415-022-11193.
    PubMed     Abstract available


  69. BATTAGLIA MA, Bezzini D, Cecchini I, Cordioli C, et al
    Patients with multiple sclerosis: a burden and cost of illness study.
    J Neurol. 2022 May 23. pii: 10.1007/s00415-022-11169.
    PubMed     Abstract available


  70. SOROSINA M, Barizzone N, Clarelli F, Anand S, et al
    A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
    J Neurol. 2022 May 12. pii: 10.1007/s00415-022-11109.
    PubMed     Abstract available


  71. HONE L, Jacobs BM, Marshall C, Giovannoni G, et al
    Age-specific effects of childhood body mass index on multiple sclerosis risk.
    J Neurol. 2022 May 9. pii: 10.1007/s00415-022-11161.
    PubMed     Abstract available


  72. SPARASCI D, Gobbi C, Castelnovo A, Riccitelli GC, et al
    Fatigue, sleepiness and depression in multiple sclerosis: defining the overlaps for a better phenotyping.
    J Neurol. 2022 May 4. pii: 10.1007/s00415-022-11143.
    PubMed     Abstract available


  73. GIANNOCCARO MP, Vacchiano V, Leone M, Camilli F, et al
    Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study.
    J Neurol. 2022 May 3. pii: 10.1007/s00415-022-11142.
    PubMed     Abstract available


  74. SANSONE G, Bonifati DM
    Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients.
    J Neurol. 2022 May 3. pii: 10.1007/s00415-022-11140.
    PubMed     Abstract available


  75. KIM H, Fraser S
    Neural correlates of dual-task walking in people with central neurological disorders: a systematic review.
    J Neurol. 2022;269:2378-2402.
    PubMed     Abstract available


  76. GELIBTER S, Bellavia G, Arbasino C, Arno N, et al
    Encephalopathy as a prognostic factor in adults with acute disseminated encephalomyelitis following COVID-19.
    J Neurol. 2022;269:2293-2300.
    PubMed     Abstract available


  77. WEISS D, Cantre D, Zettl UK, Storch A, et al
    Lethal form of a late-onset aquaporin-4 antibody-positive NMOSD related to the immune checkpoint inhibitor nivolumab.
    J Neurol. 2022;269:2778-2780.
    PubMed    


  78. HIROSE S, Hara M, Kamei S, Dalmau J, et al
    Characteristics of clinical relapses and patient-oriented long-term outcomes of patients with anti-N-methyl-D-aspartate receptor encephalitis.
    J Neurol. 2022;269:2486-2492.
    PubMed     Abstract available


    April 2022
  79. HVID LG, Stenager E, Dalgas U
    Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study.
    J Neurol. 2022 Apr 28. pii: 10.1007/s00415-022-11134.
    PubMed     Abstract available


  80. EINSIEDLER M, Kremer L, Fleury M, Collongues N, et al
    Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients.
    J Neurol. 2022 Apr 17. pii: 10.1007/s00415-022-11124.
    PubMed     Abstract available


  81. DUBBIOSO R, Bove M, Boccia D, D'Ambrosio V, et al
    Neurophysiological and behavioural correlates of ocrelizumab therapy on manual dexterity in patients with primary progressive multiple sclerosis.
    J Neurol. 2022 Apr 13. pii: 10.1007/s00415-022-11114.
    PubMed     Abstract available


  82. ZHANG Y, Yin H, Zhang D, Xu Y, et al
    Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
    J Neurol. 2022 Apr 11. pii: 10.1007/s00415-022-11118.
    PubMed     Abstract available


  83. WILLISON AG, Ruck T, Lenz G, Hartung HP, et al
    The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
    J Neurol. 2022 Apr 11. pii: 10.1007/s00415-022-11063.
    PubMed     Abstract available


  84. STORELLI L, Pagani E, Meani A, Preziosa P, et al
    Advanced diffusion-weighted imaging models better characterize white matter neurodegeneration and clinical outcomes in multiple sclerosis.
    J Neurol. 2022 Apr 10. pii: 10.1007/s00415-022-11104.
    PubMed     Abstract available


  85. CAROLUS K, Fuchs TA, Bergsland N, Ramasamy D, et al
    Time course of lesion-induced atrophy in multiple sclerosis.
    J Neurol. 2022 Apr 8. pii: 10.1007/s00415-022-11094.
    PubMed     Abstract available


  86. MOOG TM, McCreary M, Wilson A, Stanley T, et al
    Direction and magnitude of displacement differ between slowly expanding and non-expanding multiple sclerosis lesions as compared to small vessel disease.
    J Neurol. 2022 Apr 5. pii: 10.1007/s00415-022-11089.
    PubMed     Abstract available


  87. BUONOMO AR, Viceconte G, Calabrese M, De Luca G, et al
    Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
    J Neurol. 2022 Apr 4. pii: 10.1007/s00415-022-11066.
    PubMed    


  88. VANDEBERGH M, Degryse N, Dubois B, Goris A, et al
    Environmental risk factors in multiple sclerosis: bridging Mendelian randomization and observational studies.
    J Neurol. 2022 Apr 2. pii: 10.1007/s00415-022-11072.
    PubMed     Abstract available


  89. FEINSTEIN A, Amato MP, Brichetto G, Chataway J, et al
    The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience.
    J Neurol. 2022;269:1758-1763.
    PubMed     Abstract available


  90. ROJAS JI, Pappolla A, Blaya P, Marrodan M, et al
    Accumulative risk of clinical event in high-risk radiologically isolated syndrome in Argentina: data from the nationwide registry RelevarEM.
    J Neurol. 2022;269:2073-2079.
    PubMed     Abstract available


  91. ABBOUD H, Salazar-Camelo A, George N, Planchon SM, et al
    Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders.
    J Neurol. 2022;269:1786-1801.
    PubMed     Abstract available


  92. MASUDA H, Mori M, Yokouchi H, Uzawa A, et al
    Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders.
    J Neurol. 2022;269:1996-2003.
    PubMed     Abstract available


    March 2022
  93. DEANA C, Bagatto D, Battezzi A, Pecori D, et al
    Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report.
    J Neurol. 2022 Mar 30. pii: 10.1007/s00415-022-11097.
    PubMed    


  94. BISECCO A, Fornasiero A, Bianco A, Cortese A, et al
    Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
    J Neurol. 2022 Mar 27. pii: 10.1007/s00415-022-11083.
    PubMed    


  95. WENZEL N, Wittayer M, Weber CE, Schirmer L, et al
    MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions.
    J Neurol. 2022 Mar 25. pii: 10.1007/s00415-022-11082.
    PubMed     Abstract available


  96. ALLMAN M, Tallantyre E, Robertson NP
    Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies.
    J Neurol. 2022 Mar 14. pii: 10.1007/s00415-022-11053.
    PubMed    


  97. MISTRI D, Cacciaguerra L, Storelli L, Meani A, et al
    The association between cognition and motor performance is beyond structural damage in relapsing-remitting multiple sclerosis.
    J Neurol. 2022 Mar 12. pii: 10.1007/s00415-022-11044.
    PubMed     Abstract available


  98. DU Y, Li C, Hao YF, Zhao C, et al
    Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.
    J Neurol. 2022 Mar 3. pii: 10.1007/s00415-022-11048.
    PubMed     Abstract available


  99. MARIOTTINI A, Bertozzi A, Marchi L, Di Cristinzi M, et al
    Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
    J Neurol. 2022 Mar 3. pii: 10.1007/s00415-022-11003.
    PubMed     Abstract available


  100. ACHIRON A, Mandel M, Gurevich M, Dreyer-Alster S, et al
    Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
    J Neurol. 2022 Mar 2. pii: 10.1007/s00415-022-11030.
    PubMed     Abstract available


  101. KUBICKI K, Grzybowski A
    Pioneers in neurology: Charles Miller Fisher (1913-2012).
    J Neurol. 2022;269:1727-1729.
    PubMed    


  102. KANINIA S, Edey AJ, Maskell NA, Rice CM, et al
    Natalizumab-induced pneumonitis.
    J Neurol. 2022;269:1688-1690.
    PubMed    


  103. KHAN E, Shrestha AK, Colantonio MA, Liberio RN, et al
    Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature.
    J Neurol. 2022;269:1121-1132.
    PubMed     Abstract available


  104. WANG Y, Wang Y, Huo L, Li Q, et al
    SARS-CoV-2-associated acute disseminated encephalomyelitis: a systematic review of the literature.
    J Neurol. 2022;269:1071-1092.
    PubMed     Abstract available


  105. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset.
    J Neurol. 2022;269:1663-1669.
    PubMed     Abstract available


  106. XIE H, Shao Y, Du J, Song Y, et al
    Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.
    J Neurol. 2022;269:1641-1650.
    PubMed     Abstract available


  107. NISSEN MS, Orvik MS, Nilsson AC, Ryding M, et al
    NMDA-receptor encephalitis in Denmark from 2009 to 2019: a national cohort study.
    J Neurol. 2022;269:1618-1630.
    PubMed     Abstract available


  108. CACCIAGUERRA L, Storelli L, Radaelli M, Mesaros S, et al
    Application of deep-learning to the seronegative side of the NMO spectrum.
    J Neurol. 2022;269:1546-1556.
    PubMed     Abstract available


  109. HU J, Sun C, Lu J, Zhao C, et al
    Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.
    J Neurol. 2022;269:1250-1263.
    PubMed     Abstract available


  110. BONACCHI R, Meani A, Pagani E, Marchesi O, et al
    The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study.
    J Neurol. 2022 Mar 1. pii: 10.1007/s00415-022-11021.
    PubMed     Abstract available


    February 2022
  111. COBO-CALVO A, Zabalza A, Rio J, Arrambide G, et al
    Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
    J Neurol. 2022 Feb 22. pii: 10.1007/s00415-022-11019.
    PubMed    


  112. BERG-HANSEN P, Moen SM, Austeng A, Gonzales V, et al
    Sensor-based gait analyses of the six-minute walk test identify qualitative improvement in gait parameters of people with multiple sclerosis after rehabilitation.
    J Neurol. 2022 Feb 15. pii: 10.1007/s00415-022-10998.
    PubMed     Abstract available


  113. RICCARDO BA, Giulio V, Massimiliano C, Giovanna L, et al
    Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
    J Neurol. 2022 Feb 14. pii: 10.1007/s00415-022-11009.
    PubMed     Abstract available


  114. CHIARAVALLOTI ND, Costa SL, Moore NB, Costanza K, et al
    The efficacy of speed of processing training for improving processing speed in individuals with multiple sclerosis: a randomized clinical trial.
    J Neurol. 2022 Feb 12. pii: 10.1007/s00415-022-10980.
    PubMed     Abstract available


  115. SOULAGES A, Sibon I, Vallat JM, Ellie E, et al
    Neurologic manifestations of giant cell arteritis.
    J Neurol. 2022 Feb 6. pii: 10.1007/s00415-022-10991.
    PubMed     Abstract available


  116. ALCALA C, Quintanilla-Bordas C, Gascon F, Sempere AP, et al
    Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
    J Neurol. 2022 Feb 2. pii: 10.1007/s00415-022-10989.
    PubMed     Abstract available


  117. ISMAIL II, Salama S
    Association of CNS demyelination and COVID-19 infection: an updated systematic review.
    J Neurol. 2022;269:541-576.
    PubMed     Abstract available


  118. PATZIG M, Forbrig R, Kupper C, Eren O, et al
    Diagnosis and follow-up evaluation of central nervous system vasculitis: an evaluation of vessel-wall MRI findings.
    J Neurol. 2022;269:982-996.
    PubMed     Abstract available


  119. BUKHARI W, Khalilidehkordi E, Mason DF, Barnett MH, et al
    NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand.
    J Neurol. 2022;269:836-845.
    PubMed     Abstract available


  120. SPINA E, Doneddu PE, Liberatore G, Cocito D, et al
    Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP.
    J Neurol. 2022;269:907-912.
    PubMed     Abstract available


  121. BUS SRM, Broers MC, Lucke IM, Bunschoten C, et al
    Clinical outcome of CIDP one year after start of treatment: a prospective cohort study.
    J Neurol. 2022;269:945-955.
    PubMed     Abstract available


  122. LANDI D, Signori A, Cellerino M, Fenu G, et al
    What happens after fingolimod discontinuation? A multicentre real-life experience.
    J Neurol. 2022;269:796-804.
    PubMed     Abstract available


    January 2022
  123. VIRGILIO E, Vecchio D, Crespi I, Puricelli C, et al
    Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis.
    J Neurol. 2022 Jan 28. pii: 10.1007/s00415-021-10945.
    PubMed     Abstract available


  124. PROSCHINGER S, Kuhwand P, Rademacher A, Walzik D, et al
    Fitness, physical activity, and exercise in multiple sclerosis: a systematic review on current evidence for interactions with disease activity and progression.
    J Neurol. 2022 Jan 27. pii: 10.1007/s00415-021-10935.
    PubMed     Abstract available


  125. GADOTH A, Segal Y, Paran Y, Aizenstein O, et al
    The importance of tissue-based assay in the diagnosis of autoimmune encephalitis.
    J Neurol. 2022 Jan 25. pii: 10.1007/s00415-022-10973.
    PubMed     Abstract available


  126. PAPADOPOULOS D, Gklinos P, Psarros G, Drellia K, et al
    Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression.
    J Neurol. 2022 Jan 23. pii: 10.1007/s00415-021-10932.
    PubMed     Abstract available


  127. BERGAMASCHI R, Mallucci G, Fusco S, Montomoli C, et al
    Disability and mortality in a cohort of MS patients: how the real-world scenario is changed.
    J Neurol. 2022 Jan 14. pii: 10.1007/s00415-021-10940.
    PubMed    


  128. MORANO A, Cerulli Irelli E, Fanella M, Orlando B, et al
    Olfactory impairment in autoimmune encephalitis: another piece of the puzzle.
    J Neurol. 2022 Jan 10. pii: 10.1007/s00415-022-10959.
    PubMed     Abstract available


  129. COBO-CALVO A, Zabalza A, Rio J, Arrambide G, et al
    Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
    J Neurol. 2022 Jan 10. pii: 10.1007/s00415-021-10958.
    PubMed     Abstract available


  130. CRUZ RA, Varkey T, Flavia A, Samways APA, et al
    Hearing abnormalities in multiple sclerosis: clinical semiology and pathophysiologic mechanisms.
    J Neurol. 2022 Jan 9. pii: 10.1007/s00415-021-10915.
    PubMed     Abstract available


  131. KORSEN M, Pfeuffer S, Rolfes L, Meuth SG, et al
    Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.
    J Neurol. 2022 Jan 9. pii: 10.1007/s00415-021-10956.
    PubMed     Abstract available


  132. PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
    Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10951.
    PubMed     Abstract available


  133. BIGAUT K, Kremer L, Fabacher T, Ahle G, et al
    Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10950.
    PubMed     Abstract available


  134. THOMAS R, Wynford-Thomas R, Robertson NP
    Advances in the use of stem cell transplants in the treatment of multiple sclerosis.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10927.
    PubMed    


  135. TALAEI M, Robertson NP
    Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy.
    J Neurol. 2022;269:534-536.
    PubMed    


  136. ZRZAVY T, Wielandner A, Haider L, Bartsch S, et al
    FLAIR(2) post-processing: improving MS lesion detection in standard MS imaging protocols.
    J Neurol. 2022;269:461-467.
    PubMed     Abstract available


  137. XU J, Guo Y, Li J, Lv X, et al
    Progressive cortical and sub-cortical alterations in patients with anti-N-methyl-D-aspartate receptor encephalitis.
    J Neurol. 2022;269:389-398.
    PubMed     Abstract available


  138. HELMCHEN C, Buttler GM, Markewitz R, Hummel K, et al
    Acute bilateral optic/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2.
    J Neurol. 2022;269:49-54.
    PubMed    


  139. DE LOTT LB, Bennett JL, Costello F
    The changing landscape of optic neuritis: a narrative review.
    J Neurol. 2022;269:111-124.
    PubMed     Abstract available


    December 2021
  140. LEGUY S, Le Page E, Drapier S
    Elderly onset neuromyelitis optica spectrum disorder: a case report.
    J Neurol. 2021;268:4897-4898.
    PubMed    


  141. SRIWASTAVA S, Tandon M, Podury S, Prasad A, et al
    COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-COV2.
    J Neurol. 2021;268:4448-4478.
    PubMed     Abstract available


  142. KONIG N, Stetefeld HR, Dohmen C, Mergenthaler P, et al
    MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation.
    J Neurol. 2021;268:4824-4833.
    PubMed     Abstract available


  143. FLANAGAN EP
    Paraneoplastic disorders of the nervous system.
    J Neurol. 2021;268:4899-4907.
    PubMed     Abstract available


  144. CABAL-HERRERA AM, Mateen FJ
    COVID-19 in a patient treated with eculizumab for aquaporin-4 neuromyelitis optica.
    J Neurol. 2021;268:4479-4482.
    PubMed    


  145. SIRITHO S, Nopsopon T, Pongpirul K
    Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis.
    J Neurol. 2021;268:4549-4562.
    PubMed     Abstract available


  146. HOLMOY T, Hoglund RA, Illes Z, Myhr KM, et al
    Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.
    J Neurol. 2021;268:4522-4536.
    PubMed     Abstract available


    November 2021
  147. KAMBADJA B, Marion H, Cousyn L, Mezouar N, et al
    When should we test patients with epilepsy for autoimmune antibodies? Results from a French retrospective single center study.
    J Neurol. 2021 Nov 23. pii: 10.1007/s00415-021-10894.
    PubMed     Abstract available


  148. ANDERSEN LK, Jakobsson AS, Revsbech KL, Vissing J, et al
    Causes of symptom dissatisfaction in patients with generalized myasthenia gravis.
    J Neurol. 2021 Nov 21. pii: 10.1007/s00415-021-10902.
    PubMed     Abstract available


  149. RIO J, Rovira A, Gasperini C, Tintore M, et al
    Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10906.
    PubMed    


  150. LAUVSNES MB, Zetterberg H, Blennow K, Kvaloy JT, et al
    Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10893.
    PubMed     Abstract available


  151. SRIWASTAVA S, Chaudhary D, Srivastava S, Beard K, et al
    Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10910.
    PubMed     Abstract available


  152. LEHNERER S, Jacobi J, Schilling R, Grittner U, et al
    Burden of disease in myasthenia gravis: taking the patient's perspective.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10891.
    PubMed     Abstract available


  153. CHAMBERLAIN JL, Huda S, Whittam DH, Matiello M, et al
    Correction to: Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.
    J Neurol. 2021 Nov 15. pii: 10.1007/s00415-021-10896.
    PubMed    


  154. MCHATTIE AW, Coebergh J, Khan F, Morgante F, et al
    Palilalia as a prominent feature of anti-NMDA receptor encephalitis in a woman with COVID-19.
    J Neurol. 2021;268:3995-3997.
    PubMed    


    October 2021
  155. FUCHS TA, Schoonheim MM, Broeders TAA, Hulst HE, et al
    Functional network dynamics and decreased conscientiousness in multiple sclerosis.
    J Neurol. 2021 Oct 29. pii: 10.1007/s00415-021-10860.
    PubMed     Abstract available


  156. WASHINGTON F, Langdon D
    Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review.
    J Neurol. 2021 Oct 21. pii: 10.1007/s00415-021-10850.
    PubMed     Abstract available


  157. ALSCHULER KN, Whibley D, Kratz AL, Jensen MP, et al
    Quality of life in individuals newly diagnosed with multiple sclerosis or clinically isolated syndrome.
    J Neurol. 2021 Oct 19. pii: 10.1007/s00415-021-10842.
    PubMed     Abstract available


  158. BURT RK, Han X, Quigley K, Helenowski IB, et al
    Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis.
    J Neurol. 2021 Oct 11. pii: 10.1007/s00415-021-10820.
    PubMed     Abstract available


  159. FILIPPI M, Danesi R, Derfuss T, Duddy M, et al
    Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis.
    J Neurol. 2021 Oct 9. pii: 10.1007/s00415-021-10836.
    PubMed     Abstract available


  160. PREZIOSA P, Conti L, Rocca MA, Filippi M, et al
    Effects on cognition of DMTs in multiple sclerosis: moving beyond the prevention of inflammatory activity.
    J Neurol. 2021 Oct 7. pii: 10.1007/s00415-021-10832.
    PubMed     Abstract available


  161. AL-ANSARI A, Robertson NP
    Autoimmune encephalitis: clinical presentation, investigation and treatment.
    J Neurol. 2021;268:3935-3937.
    PubMed    


  162. FUKAMI Y, Iijima M, Koike H, Yamada S, et al
    Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients.
    J Neurol. 2021;268:3835-3844.
    PubMed     Abstract available


  163. JARIUS S, Wilken D, Haas J, Ruprecht K, et al
    Parvovirus B19 and mumps virus antibodies are major constituents of the intrathecal immune response in European patients with MS and increase the diagnostic sensitivity and discriminatory power of the MRZ reaction.
    J Neurol. 2021;268:3758-3765.
    PubMed     Abstract available


  164. QUEROL L, Crabtree M, Herepath M, Priedane E, et al
    Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP).
    J Neurol. 2021;268:3706-3716.
    PubMed     Abstract available


  165. RIO J, Rovira A, Gasperini C, Tintore M, et al
    Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
    J Neurol. 2021 Oct 1. pii: 10.1007/s00415-021-10823.
    PubMed     Abstract available


    September 2021
  166. AHMED A, Kok ZQ, Coles A, Scoffings DJ, et al
    Susac's syndrome as an autoimmune complication of alemtuzumab-associated immune reconstitution.
    J Neurol. 2021 Sep 29. pii: 10.1007/s00415-021-10802.
    PubMed    


  167. PUTHENPARAMPIL M, Perini P, Bergamaschi R, Capobianco M, et al
    Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors.
    J Neurol. 2021 Sep 27. pii: 10.1007/s00415-021-10782.
    PubMed     Abstract available


  168. PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
    Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies.
    J Neurol. 2021 Sep 17. pii: 10.1007/s00415-021-10803.
    PubMed     Abstract available


  169. BOZOVIC I, Ilic Zivojinovic J, Peric S, Kostic M, et al
    Long-term outcome in patients with myasthenia gravis: one decade longitudinal study.
    J Neurol. 2021 Sep 4. pii: 10.1007/s00415-021-10759.
    PubMed     Abstract available


  170. BERCIANO J
    Pathogenic events in very early Guillain-Barre syndrome: neither demyelination nor axonal degeneration but endoneurial inflammatory oedema.
    J Neurol. 2021 Sep 3. pii: 10.1007/s00415-021-10773.
    PubMed    


  171. ANDERSEN MA, Buron MD, Magyari M
    Late-onset MS is associated with an increased rate of reaching disability milestones.
    J Neurol. 2021;268:3352-3360.
    PubMed     Abstract available


  172. HOFSTADT-VAN OY U, Stankovic S, Kelbel C, Oswald D, et al
    Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19.
    J Neurol. 2021;268:3125-3128.
    PubMed     Abstract available


  173. VAN LOOY E, Veenker L, Steyaert A, Leenders J, et al
    COVID-19-induced exacerbation of chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2021;268:3129-3131.
    PubMed    


    August 2021
  174. SUN J, Xie Y, Wang Q, Shen J, et al
    Genes associated with grey matter volume reduction in multiple sclerosis.
    J Neurol. 2021 Aug 29. pii: 10.1007/s00415-021-10777.
    PubMed     Abstract available


  175. BLOCK VJ, Pitsch EA, Gopal A, Zhao C, et al
    Identifying falls remotely in people with multiple sclerosis.
    J Neurol. 2021 Aug 17. pii: 10.1007/s00415-021-10743.
    PubMed     Abstract available


  176. MARGONI M, Preziosa P, Filippi M, Rocca MA, et al
    Anti-CD20 therapies for multiple sclerosis: current status and future perspectives.
    J Neurol. 2021 Aug 11. pii: 10.1007/s00415-021-10744.
    PubMed     Abstract available


  177. ALVINO B, Arianna F, Assunta B, Antonio C, et al
    Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
    J Neurol. 2021 Aug 4. pii: 10.1007/s00415-021-10737.
    PubMed     Abstract available


  178. PARDO G, Coates S, Okuda DT
    Outcome measures assisting treatment optimization in multiple sclerosis.
    J Neurol. 2021 Aug 2. pii: 10.1007/s00415-021-10674.
    PubMed     Abstract available


  179. FIONDA L, Di Pasquale A, Morino S, Leonardi L, et al
    Changes of clinical, neurophysiological and nerve ultrasound characteristics in CIDP over time: a 3-year follow-up.
    J Neurol. 2021;268:3011-3019.
    PubMed     Abstract available


  180. CORTESE R, Prosperini L, Stasolla A, Haggiag S, et al
    Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy.
    J Neurol. 2021;268:2895-2899.
    PubMed     Abstract available


  181. CILINGIR V, Batur M
    First measured retinal nerve fiber layer thickness in RRMS can be used as a biomarker for the course of the disease: threshold value discussions.
    J Neurol. 2021;268:2858-2865.
    PubMed     Abstract available


  182. WANSCHITZ JV, Kaml M, Pfausler B, Helbok R, et al
    Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up.
    J Neurol. 2021;268:2700-2702.
    PubMed    


    July 2021
  183. O SULLIVAN C, Zach F, Moser T, Pilz G, et al
    Misinterpretation of glioblastoma as ADEM: potentially harmful consequences of over-diagnosis of COVID-19 vaccine-associated adverse events.
    J Neurol. 2021 Jul 24. pii: 10.1007/s00415-021-10707.
    PubMed    


  184. FERRARO D, Iaffaldano P, Guerra T, Inglese M, et al
    Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
    J Neurol. 2021 Jul 22. pii: 10.1007/s00415-021-10708.
    PubMed     Abstract available


  185. RAUMA I, Mustonen T, Seppa JM, Ukkonen M, et al
    Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients.
    J Neurol. 2021 Jul 13. pii: 10.1007/s00415-021-10664.
    PubMed     Abstract available


  186. NIESSEN A, Schwarz B, Urban M, Kramer S, et al
    Aseptic meningitis after glatiramer acetate.
    J Neurol. 2021;268:2589-2590.
    PubMed    


  187. STARMANS NLP, van Dijk MR, Kappelle LJ, Frijns CJM, et al
    Sneddon syndrome: a comprehensive clinical review of 53 patients.
    J Neurol. 2021;268:2450-2457.
    PubMed     Abstract available


  188. MASUCCIO FG, Barra M, Claudio G, Claudio S, et al
    A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection.
    J Neurol. 2021;268:2327-2330.
    PubMed     Abstract available


    June 2021
  189. CHISARI CG, Comi G, Filippi M, Paolicelli D, et al
    PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10676.
    PubMed     Abstract available


  190. SANKARI SE, Van Essche C, van Pesch V
    Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10679.
    PubMed    


  191. KOGEL AK, Gold R, Schneider R
    CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
    J Neurol. 2021 Jun 27. pii: 10.1007/s00415-021-10661.
    PubMed    


  192. S G, S L, C Z, A N, et al
    Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.
    J Neurol. 2021 Jun 26. pii: 10.1007/s00415-021-10663.
    PubMed     Abstract available


  193. HANNINEN K, Viitala M, Atula S, Laakso SM, et al
    Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study.
    J Neurol. 2021 Jun 25. pii: 10.1007/s00415-021-10673.
    PubMed     Abstract available


  194. HAVLA J, Schultz Y, Zimmermann H, Hohlfeld R, et al
    First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
    J Neurol. 2021 Jun 11. pii: 10.1007/s00415-021-10648.
    PubMed    


  195. KIM SH, Baek SH, Lee SU, Yu S, et al
    Optic disc edema as a sole manifestation of anti-GQ1b antibody syndrome.
    J Neurol. 2021;268:2263-2266.
    PubMed    


  196. DAO LM, Machule ML, Bacher P, Hoffmann J, et al
    Decreased inflammatory cytokine production of antigen-specific CD4(+) T cells in NMDA receptor encephalitis.
    J Neurol. 2021;268:2123-2131.
    PubMed     Abstract available


  197. LLORENTE AYUSO L, Torres Rubio P, Beijinho do Rosario RF, Giganto Arroyo ML, et al
    Bickerstaff encephalitis after COVID-19.
    J Neurol. 2021;268:2035-2037.
    PubMed    


    May 2021
  198. JURYNCZYK M, Klimiec-Moskal E, Kong Y, Hurley S, et al
    Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis.
    J Neurol. 2021 May 27. pii: 10.1007/s00415-021-10619.
    PubMed     Abstract available


  199. CHEN MH, Chiaravalloti ND, DeLuca J
    Neurological update: cognitive rehabilitation in multiple sclerosis.
    J Neurol. 2021 May 24. pii: 10.1007/s00415-021-10618.
    PubMed     Abstract available


  200. HOU Y, Shao K, Yan Y, Dai T, et al
    Anti-HMGCR myopathy overlaps with dermatomyositis-like rash: a distinct subtype of idiopathic inflammatory myopathy.
    J Neurol. 2021 May 21. pii: 10.1007/s00415-021-10621.
    PubMed     Abstract available


  201. KILIC MA, Yoruk Yildirim ZN, Oner A, Yesil E, et al
    Pediatric LGI1 and CASPR2 autoimmunity associated with COVID 19: Morvan syndrome.
    J Neurol. 2021 May 18. pii: 10.1007/s00415-021-10614.
    PubMed    


  202. ZRZAVY T, Pfitzner A, Flachenecker P, Rommer P, et al
    Effects of normobaric hypoxic endurance training on fatigue in patients with multiple sclerosis: a randomized prospective pilot study.
    J Neurol. 2021 May 18. pii: 10.1007/s00415-021-10596.
    PubMed     Abstract available


  203. HILDESHEIM FE, Benedict RHB, Zivadinov R, Dwyer MG, et al
    Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis.
    J Neurol. 2021 May 16. pii: 10.1007/s00415-021-10594.
    PubMed     Abstract available


  204. TOMMASIN S, Cocozza S, Taloni A, Gianni C, et al
    Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis.
    J Neurol. 2021 May 10. pii: 10.1007/s00415-021-10605.
    PubMed     Abstract available


  205. RUGGIERI S, Petracca M, De Giglio L, De Luca F, et al
    A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis.
    J Neurol. 2021 May 3. pii: 10.1007/s00415-021-10576.
    PubMed     Abstract available


  206. THOUIN A, Gastaldi M, Woodhall M, Jacobson L, et al
    Comparison of N-methyl-D-aspartate receptor antibody assays using live or fixed substrates.
    J Neurol. 2021;268:1818-1826.
    PubMed     Abstract available


    April 2021
  207. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    J Neurol. 2021 Apr 22. pii: 10.1007/s00415-021-10559.
    PubMed     Abstract available


  208. COVEY TJ, Golan D, Doniger GM, Sergott R, et al
    Visual evoked potential latency predicts cognitive function in people with multiple sclerosis.
    J Neurol. 2021 Apr 18. pii: 10.1007/s00415-021-10561.
    PubMed     Abstract available


  209. CENTONZE D, Rocca MA, Gasperini C, Kappos L, et al
    Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
    J Neurol. 2021 Apr 12. pii: 10.1007/s00415-021-10545.
    PubMed     Abstract available


  210. WILF-YARKONI A, Lotan I, Steiner I, Hellmann MA, et al
    Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis.
    J Neurol. 2021 Apr 7. pii: 10.1007/s00415-021-10544.
    PubMed     Abstract available


  211. NYGAARD MKE, Langeskov-Christensen M, Dalgas U, Eskildsen SF, et al
    Cortical diffusion kurtosis imaging and thalamic volume are associated with cognitive and walking performance in relapsing-remitting multiple sclerosis.
    J Neurol. 2021 Apr 7. pii: 10.1007/s00415-021-10543.
    PubMed     Abstract available


  212. URBAIN F, Puyade M, Labeyrie C, Maubeuge N, et al
    Hematopoietic stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: French experience about four patients, under the behalf of French society for bone marrow transplantation.
    J Neurol. 2021;268:1536-1539.
    PubMed    


  213. KAPOOR M, Keh R, Compton L, Morrow S, et al
    Subcutaneous immunoglobulin dose titration to clinical response in inflammatory neuropathy.
    J Neurol. 2021;268:1485-1490.
    PubMed     Abstract available


  214. NETRAVATHI M, Holla VV, Nalini A, Yadav R, et al
    Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder.
    J Neurol. 2021;268:1419-1433.
    PubMed     Abstract available


  215. CHAUDHARY UJ, Rajabally YA
    Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2021;268:1366-1373.
    PubMed     Abstract available


    March 2021
  216. VAN ROSMALEN MHJ, Goedee HS, van der Gijp A, Witkamp TD, et al
    Quantitative assessment of brachial plexus MRI for the diagnosis of chronic inflammatory neuropathies.
    J Neurol. 2021;268:978-988.
    PubMed     Abstract available


  217. MATHIS S, Soulages A, Le Masson G, Vallat JM, et al
    Epidemics and outbreaks of peripheral nervous system disorders: I. infectious and immune-mediated causes.
    J Neurol. 2021;268:879-890.
    PubMed     Abstract available


    February 2021
  218. YOO JS, Kim YS, Kim HY, Kwon HS, et al
    Comparison of patients with transient and sustained increments of antiphospholipid antibodies after acute ischemic stroke.
    J Neurol. 2021 Feb 6. pii: 10.1007/s00415-021-10432.
    PubMed     Abstract available


  219. MARTIN T, Duke S, Kumar V, Fadhil A, et al
    NMDAR antibody encephalitis overlapping with CLIPPERS syndrome in a psoriasis patient on adalimumab.
    J Neurol. 2021;268:714-716.
    PubMed    


  220. SCHROTER N, Weiller C, Rauer S, Waller CF, et al
    Anti-glycin-receptor antibody related stiff-person syndrome under treatment with an immune checkpoint inhibitor.
    J Neurol. 2021;268:709-711.
    PubMed    


  221. OKADA K, Seki M, Yaguchi H, Sakuta K, et al
    Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature.
    J Neurol. 2021;268:680-688.
    PubMed     Abstract available


  222. BERGMAN J, Burman J, Bergenheim T, Svenningsson A, et al
    Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.
    J Neurol. 2021;268:651-657.
    PubMed     Abstract available


    January 2021
  223. STOECKLEIN VM, Kellert L, Patzig M, Kupper C, et al
    Extended stereotactic brain biopsy in suspected primary central nervous system angiitis: good diagnostic accuracy and high safety.
    J Neurol. 2021;268:367-376.
    PubMed     Abstract available


  224. KASS-ILIYYA L, Snowden JA, Thorpe A, Jessop H, et al
    Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience.
    J Neurol. 2021;268:265-275.
    PubMed     Abstract available


    July 2020
  225. BIEN CG, Bien CI, Dogan Onugoren M, De Simoni D, et al
    Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome.
    J Neurol. 2020;267:2101-2114.
    PubMed     Abstract available


  226. MUNIZ-CASTRILLO S, Ambati A, Dubois V, Vogrig A, et al
    Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies.
    J Neurol. 2020;267:1906-1911.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: